Physician
Pathology
Dr. Alan E. Mast, MD
|
|
Give Review
Alan E. Mast, MD practices Pathology. He went to Duke University School of Medicine. Duke University School of Medicine is a one of the best medicals schools. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. Alan Mast is also published. He has 67 publications published. The lastest publication: "Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations.' He is registered with Medicare and accepts Medicare payments.
Publications
- Oral iron supplementation after blood donation: a randomized clinical trial.
- The health implications of low hemoglobin deferral in infrequent blood donors.
- The strategies to reduce iron deficiency in blood donors randomized trial: design, enrolment and early retention.
- Biology of tissue factor pathway inhibitor.
- Low hemoglobin deferral in blood donors.
- Protein S Is a Cofactor for Platelet and Endothelial Tissue Factor Pathway Inhibitor-α but Not for Cell Surface-Associated Tissue Factor Pathway Inhibitor.
- Translation of Human Tissue Factor Pathway Inhibitor-β mRNA Is Controlled by Alternative Splicing Within the 5' Untranslated Region.
- Acquired factor V deficiency in a patient without evidence of a classical inhibitor.
- Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.
- Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor.
- Restless legs syndrome, pica, and iron status in blood donors.
- Laboratory variables for assessing iron deficiency in REDS-II Iron Status Evaluation (RISE) blood donors.
- Comparison of the inhibitory activity of human TFPI? and TFPI?
- Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome.
- Population-based screening for anemia using first-time blood donors.
- Tissue factor pathway inhibitor is an inhibitor of Factor VII-activating protease.
- Caveolae Optimize Tissue Factor-Factor VIIa Inhibitory Activity of Cell Surface Associated Tissue Factor Pathway Inhibitor.
- Curbing an inhibitor for hemostasis.
- Blood center practice and education for blood donors with anemia.
- Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth.
- Evaluating surface bound rTFPI through an in vitro model of vessel wall injury.
- Alternatively spliced tissue factor pathway inhibitor: Functional Implications.
- Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis.
- Alternatively spliced isoforms of tissue factor pathway inhibitor.
- Community blood donors' knowledge of anemia and design of a literacy-appropriate educational intervention.
- Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors.
- Reticulocyte hemoglobin content.
- Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.
- Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells.
- In vitro flow evaluation of recombinant tissue factor pathway inhibitor immobilized on collagen impregnated Dacron.
- Characterization of the association of tissue factor pathway inhibitor with human placenta.
- Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
- Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency.
- A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule.
- Molecular evolution of receptor-like kinase genes in hexaploid wheat. Independent evolution of orthologs after polyploidization and mechanisms of local rearrangements ...
- Proteolytic inactivation of alpha-1-anti-chymotrypsin. Sites of cleavage and generation of chemotactic activity.
- In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II.
- Polyethylene glycol modification of serpins improves therapeutic potential.
- Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass.
- Tissue factor pathway inhibitor revisited.
- Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential.
- Conformation of the reactive site loop of alpha 1-proteinase inhibitor probed by limited proteolysis.
- Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (...
- Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-pr...
- The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.
- Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity.
- Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase.
- Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations.
- A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression.
- Tissue factor pathway inhibitor and bacterial infection.
- Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice.
- Tissue factor pathway inhibitor binds to platelet thrombospondin-1.
- Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor.
- Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans.
- Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition.
- Thrombophilia and pregnancy failure: feto-maternal interactions in the vascular bed of the placenta.
- Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
- Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity.
- Profiling constitutive proteolytic events in vivo.
- Factor Xa inhibition by immobilized recombinant tissue factor pathway inhibitor.
- Expression of tissue factor pathway inhibitor by endothelial cells and platelets.
- Biospecimen repositories: are blood donors willing to participate?
- Demographic correlates of low hemoglobin deferral among prospective whole blood donors.
- Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study.
- The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*.
- Donation return time at fixed and mobile donation sites.
Schools
Duke University
Doctors Specialties
- Clinical Pathology
- Pathology
Accepted Insurances
Education
-
Washington University - Barnes-Jewish Hospital -
Duke University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Heidi Bertram, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret M. Anderson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Urias A. Almagro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence J. Clowry Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander C. MacKinnon Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay F. Schamberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janice G. McFarland, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mahir Z. Bagirov, MD |
|
|
Dr. Luis F. Carrillo, MD |
|
|
Dr. Daniel J. Rowan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Mehraboon S. Irani, MB BCH
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danielle Vargas De Stefano, MD
This Doctor is OpenDoctor Recommended.
|